RICHMOND, Va. / Nov 29, 2023 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) (the “Company”) today announced that it will host an Investor Day for investors and research analysts on Wednesday, December 6th at Convene in Boston, Massachusetts. The event will feature presentations from members of the senior executive leadership team, who will share the Company’s strategic vision, operating and growth strategy, and multi-year financial targets.
The event will begin at 8:30 a.m. Eastern Standard Time (EST) and is expected to conclude at 12:00 p.m. EST. Due to limited capacity, in-person attendance is by invitation only. A live broadcast and on-demand replay of the event will be available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers, and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio, an Americas-based manufacturing footprint for personal protective equipment (PPE) and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at https://www.linkedin.com/company/owens-&-minor/.
| Last Trade: | US$2.69 |
| Daily Change: | 0.09 3.46 |
| Daily Volume: | 1,828,630 |
| Market Cap: | US$208.070M |
October 30, 2025 October 07, 2025 September 15, 2025 August 11, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load